What are the treatment options for obstructive sleep apnea (OSA) in adults?

Treatment Options for Obstructive Sleep Apnea

Positive airway pressure (PAP) therapy is the first-line treatment for adults with moderate-to-severe OSA (AHI ≥15 events/hour), and should be initiated using either auto-adjusting PAP (APAP) at home or in-laboratory PAP titration for patients without significant comorbidities 1, 2.

Primary Treatment: PAP Therapy

Indications for PAP

• Strongly recommended for moderate-to-severe OSA (AHI ≥15 events/hour) 1, 2
• Consider for mild OSA (AHI 5-14 events/hour) if patient has:
  • Cardiovascular or cerebrovascular disease
  • Hypertension or diabetes
  • COPD
  • Prominent symptoms (excessive daytime sleepiness, cognitive impairment, insomnia, depression)
  • Perioperative status 2

PAP Modality Selection

CPAP is the default modality due to lower cost, as CPAP, APAP, and BPAP show comparable efficacy, safety, and adherence 2.

Use APAP instead of CPAP for:

• CPAP intolerance
• Positional or sleep-stage dependent OSA
• Alcohol-related OSA
• Significant weight fluctuations 2

Use BPAP when:

• Obstructive events persist at CPAP pressures ≥15 cmH₂O
• Patient cannot tolerate high CPAP pressures
• OSA coexists with chronic hypoventilation (COPD, neuromuscular disease, obesity hypoventilation syndrome) 2

PAP Initiation Method

Either home APAP or in-laboratory titration is acceptable for patients without significant comorbidities 1. This recommendation excludes patients with:

• Congestive heart failure
• Chronic opiate use
• Significant lung disease (COPD)
• Neuromuscular disease
• History of uvulopalatopharyngoplasty
• Sleep-related oxygen requirements
• Central sleep apnea syndromes 1

For these complex patients, in-laboratory manual titration is preferred over auto-titration 2.

Evidence for PAP in Specific Populations

Sleepy patients with OSA: PAP clearly improves sleepiness, quality of life, and adherence is generally acceptable 1.

Non-sleepy patients with hypertension: PAP produces clinically significant blood pressure reductions, particularly in nocturnal measurements, with moderate quality evidence. The benefits likely outweigh harms for most patients with comorbid hypertension 1.

Non-sleepy patients without hypertension: There is insufficient evidence to recommend or withhold PAP for reducing cardiovascular events or mortality. Meta-analyses of RCTs showed no significant improvements in CV events or mortality, despite observational studies suggesting benefit. Conservative management with monitoring may be appropriate for these patients 1.

Alternative and Adjunctive Treatments

Oral Appliance Therapy

Recommended for:

• Primary snoring and mild-to-moderate OSA 3, 2
• Alternative or adjunct for patients with poor PAP tolerance or adherence 3, 2

Custom-made oral appliances are preferred over non-custom devices to improve adherence and effectiveness 2.

Lifestyle Interventions

Recommended for ALL patients 2:

• Dietary control and weight management (BMI-based stepwise strategy)
• Alcohol avoidance
• Smoking cessation
• Avoid sedative-hypnotic agents
• Sleep hygiene and regular physical activity
• Positional therapy for position-dependent OSA 2

Oropharyngeal Myofunctional Therapy

Recommended as adjunct or combined therapy in patients with OSA 3, 2.

Upper Airway Surgery

May be considered for adults with significant anatomical abnormalities who are intolerant or nonadherent to PAP therapy, after careful evaluation of benefits and risks 3, 2, 4. Specific procedures include:

• Maxillo-mandibular osteotomy 3
• Hypoglossal nerve stimulation 3
• Procedures addressing anatomical obstruction (narrow pharyngeal airway, adenoid hypertrophy) 5

Pharmacological Therapy

Not recommended as routine treatment for all adults with OSA 2.

For OSA-related excessive daytime sleepiness (residual despite adequate PAP therapy):

• Solriamfetol is recommended (strongest evidence) 2
• Modafinil is recommended as alternative 2

For COMISA (comorbid insomnia and sleep apnea):

• Short-term non-benzodiazepine hypnotics may be considered with close monitoring 2
• Benzodiazepines are NOT recommended 2

For OSA with obesity (moderate-to-severe OSA with inadequate weight control):

• Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) may be considered as adjunctive therapy 2

Gastric Bypass Surgery

Addressed in the European guideline as an option for appropriate candidates 3.

Common Pitfalls

1. Do not use PAP therapy to reduce cardiovascular events in asymptomatic patients - the RCT evidence does not support this indication 1

2. Do not use home sleep apnea testing (HSAT) to rule out OSA - it can diagnose moderate-to-severe uncomplicated OSA but cannot exclude the diagnosis 2

3. Do not prescribe wake-promoting agents without ensuring PAP adherence is optimized first - residual sleepiness should only be treated pharmacologically after adequate PAP therapy 2

4. Ensure proper follow-up for PAP therapy - visits at 1 week, 1 month, and 3 months are recommended, then every 6-12 months if stable. Telemedicine and remote monitoring improve adherence 2